Chelsea Counsel Company’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28.7K | Hold |
114
| – | – | 0.01% | 149 |
|
|
2026
Q1 | $24.8K | Hold |
114
| – | – | 0.01% | 157 |
|
|
2025
Q4 | $26K | Hold |
114
| – | – | 0.01% | 148 |
|
|
2025
Q3 | $26.4K | Buy |
+114
| New | +$23.2K | 0.01% | 154 |
|
|
2023
Q1 | – | Sell |
-80
| Closed | -$12.9K | – | 151 |
|
|
2022
Q4 | $12.9K | Buy |
+80
| New | +$12.3K | 0.01% | 144 |
|
|
2022
Q3 | – | Sell |
-1,700
| Closed | -$260K | – | 82 |
|
|
2022
Q2 | $260K | Hold |
1,700
| – | – | 0.13% | 87 |
|
|
2022
Q1 | $276K | Hold |
1,700
| – | – | 0.12% | 86 |
|
|
2021
Q4 | $230K | Buy |
+1,700
| New | +$201K | 0.1% | 93 |
|
|
2018
Q3 | – | Sell |
-2,280
| Closed | -$211K | – | 77 |
|
|
2018
Q2 | $211K | Sell |
2,280
-100
| -4% | -$9.77K | 0.13% | 74 |
|
|
2018
Q1 | $225K | Hold |
2,380
| – | – | 0.14% | 64 |
|
|
2017
Q4 | $230K | Hold |
2,380
| – | – | 0.12% | 75 |
|
|
2017
Q3 | $211K | Sell |
2,380
-800
| -25% | -$60.9K | 0.11% | 77 |
|
|
2017
Q2 | $231K | Hold |
3,180
| – | – | 0.12% | 74 |
|
|
2017
Q1 | $207K | Sell |
3,180
-831
| -21% | -$52.2K | 0.11% | 77 |
|
|
2016
Q4 | $251K | Hold |
4,011
| – | – | 0.13% | 80 |
|
|
2016
Q3 | $253K | Sell |
4,011
-751
| -16% | -$48.6K | 0.13% | 83 |
|
|
2016
Q2 | $295K | Hold |
4,762
| – | – | 0.13% | 85 |
|
|
2016
Q1 | $272K | Hold |
4,762
| – | – | 0.09% | 109 |
|
|
2015
Q4 | $282K | Sell |
4,762
-2,831
| -37% | -$163K | 0.09% | 115 |
|
|
2015
Q3 | $413K | Sell |
7,593
-1
| -0% | -$65 | 0.1% | 101 |
|
|
2015
Q2 | $510K | Buy |
7,594
+1,363
| +22% | +$89K | 0.11% | 85 |
|
|
2015
Q1 | $365K | Hold |
6,231
| – | – | 0.08% | 99 |
|
|
2014
Q4 | $408K | Buy |
6,231
+415
| +7% | +$26.2K | 0.08% | 93 |
|
|
2014
Q3 | $336K | Sell |
5,816
-171,159
| -97% | -$9.5M | 0.07% | 100 |
|
|
2014
Q2 | $9.99M | Buy |
176,975
+1,500
| +0.9% | +$78.7K | 1.95% | 21 |
|
|
2014
Q1 | $9.02M | Buy |
175,475
+1,806
| +1% | +$91.3K | 1.83% | 22 |
|
|
2013
Q4 | $9.17M | Sell |
173,669
-9,243
| -5% | -$454K | 2.17% | 19 |
|
|
2013
Q3 | $8.18M | Buy |
182,912
+355
| +0.2% | +$15.7K | 1.7% | 25 |
|
|
2013
Q2 | $7.55M | Buy |
+182,557
| New | +$7.98M | 1.98% | 22 |
|
Other funds holding ABBV
Chelsea Counsel Company's ABBV Position: Q2 2026 in Review
Chelsea Counsel Company held its AbbVie (ABBV) position steady in Q2 2026 at 114 shares worth $28.7K. The position accounts for 0.01% of the portfolio, ranked #149.
Chelsea Counsel Company first reported a position in ABBV in Q2 2013 and has held it in 29 quarters since. The position peaked at $9.99M in Q2 2014. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Chelsea Counsel Company held 114 shares of AbbVie worth $28.7K as of Q2 2026.
- Chelsea Counsel Company left its AbbVie share count unchanged in Q2 2026.
- AbbVie made up 0.01% of Chelsea Counsel Company's portfolio in Q2 2026, its #149 holding.
- Chelsea Counsel Company first reported a position in AbbVie in Q2 2013 and has held it in 29 quarters since.
- Chelsea Counsel Company's AbbVie position peaked at $9.99M in Q2 2014.
- 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Chelsea Counsel Company's 13F filing for Q2 2026, filed 12 Aug 2026.